Servicios Personalizados
Revista
Articulo
Indicadores
Citado por SciELO
Accesos
Links relacionados
Similares en SciELO
Compartir
Revista de Obstetricia y Ginecología de Venezuela
versión impresa ISSN 0048-7732
Resumen
DONNINO, Ana et al. Efecto de la terapia hormonal combinada (drospirenona / 17 β -estradiol) sobre el peso corporal en posmenopáusicas. Rev Obstet Ginecol Venez [online]. 2013, vol.73, n.4, pp.225-233. ISSN 0048-7732.
Objective: To compare the effects of combined hormonal therapy (drospirenone/17 β-estradiol) versus a placebo on body weight and other anthropometric variables in postmenopausal women assisted in the gynecology consultation at the Hospital Dr. Manuel Noriega Trigo, in Zulia state, Venezuela. Methods: A quasi-experimental, case control, randomized, single blind study, which involved 120 postmenopausal women, divided into two groups to receive a daily dose for 6 months of combined hormone therapy (group A; drospirenone 2 mg/ 17 β-estradiol) or placebo (group B). We evaluated body weight, body mass index, waist circumference and waist-hip ratio, before and at the end of treatment. Results: We showed that in the group receiving hormonal therapy with drospirenone / 17 β-estradiol was a reduction of about 3 kg in mean body weight after 6 months of treatment (79,80 ± 9,35 vs. 76,33 ± 8,36; P <0,001); and a significant reduction in body mass index (30,12 ± 02,02 vs. 28,72 ± 1,79; P <0,001), abdominal circumference (120,10 ± 14,73 vs. 110,10 ± 14,00; P <0,001) and waist hip (0,87 ± 0,04 vs. 0,84 ± 0,07; P <0;05). In the group receiving a placebo had no significant changes in these variables. Conclusions: Hormonal therapy with drospirenone / 17 β-estradiol was associated with a significant reduction in body weight, body mass index, waist circumference and waist-hip ratio after 6 months of treatment in postmenopausal women, with few or mild side effects.
Palabras clave : Waist circumference; Drospirenone; Body mass index; Menopause; Body weight.